Demand for advanced therapies in Europe is growing as populations age and the burden of chronic, autoimmune and rare diseases rises, WuXi Biologics said. The company said the European biologics market was valued at an estimated US$123.75 billion in 2025 and is projected to grow at a compound annual rate of 8.1% from 2026 to 2035, reaching approximately US$269.65 billion.
At CPHI Milan 2026, which the company said brought together more than 62,000 pharmaceutical professionals and 2,900 exhibitors, WuXi Biologics said it met global biopharma partners on moving complex biologics from development to supply. As of June 2026, the company said it had passed 49 regulatory inspections, 23 of them by the FDA and EMA, secured 166 facility license approvals, and passed more than 2,000 GMP quality audits by clients, including over 280 conducted by EU Qualified Persons.
The company said its Dundalk site in Ireland is its established commercial manufacturing hub in Europe, operating under an HPRA GMP manufacturing license and supporting EMA-approved commercial products. It has served more than 10 clients and provides 54,000 L of drug-substance capacity across perfusion and fed-batch platforms, the company said, and in 2026 it secured multiple new large-scale manufacturing projects and began the associated technology transfers. The site received the ISPE Facility of the Year Award in 2023, while in 2026 WuXi Biologics Ireland received an Overall Excellence in Life Sciences Award and its MSAT team was named Life Sciences Team of the Year.
WuXi Biologics said its Wuppertal site in North Rhine-Westphalia, Germany, offers drug-substance manufacturing at different scales and stages of development, with 12,000 L of single-use bioreactor capacity and potential to expand to 24,000 L, together with GMP-certified quality-control laboratories and warehousing. The two European sites are joined by globally aligned technology, quality and execution systems, the company said, within a network that also covers the United States, China and Singapore and includes a Global Dual Sourcing approach that aligns quality, analytics and technology transfer across sites.
As of June 2026, the company said it was supporting 1,064 integrated projects, including 221 bispecific and multi-specific antibody projects and 328 antibody-drug conjugate projects, with complex modalities accounting for more than half of the portfolio. It said more than 66 DNA-to-IND projects had been completed within six months with a 100% IND-filing success rate, that a client project can be initiated within four weeks, that technology transfer to process performance qualification has been completed in as little as 3.5 months, and that it has a 100% PPQ campaign success rate, with 34 PPQs scheduled for 2026 and 30 for 2027.
